Appendicitis
Conditions
Brief summary
To assess the efficacy, safety, tissue distribution of target organ and Population Pharmacokinetic (PPK) of morinidazole and sodium chloride injection with surgery in patients with suppurative or gangrenous appendicitis
Detailed description
Acute appendicitis is among the most common cause of acute abdominal pain. In patients with complicated acute appendicitis, postoperative, broad-spectrum antibiotics are always recommended. Metronidazole, a member of the nitroimidazole drug class, is included in the regimens recommended for improving anaerobic bacteria coverage. The sideeffects of metronidazole include a metallic taste, nausea, transient neutropenia, and peripheral neuropathy. Antimicrobial resistance to metronidazole has emerged after several decades of worldwide use of the drug. Morinidazole, a National Class I Antimicrobial, is a new type of third-generation nitroimidazole antimicrobial that is used for treating amoebiasis, trichomoniasis, and anaerobic bacterial infections, and which exhibits greater activity and less toxicity than metronidazole. Morinidazole and Sodium Chloride Injection used in pelvic inflammatory disease or appendicitis cases had been approved by CFDA in 2014. This phase 4 study is to assess the efficacy, safety, tissue distribution of target organ and Population Pharmacokinetic (PPK) of morinidazole in patients with suppurative or gangrenous appendicitis.
Interventions
DRUGmorinidazole
morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
Sponsors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* 18 and 65 years old * A diagnosis of suppurative or gangrenous appendicitis based on: 1. metastatic right lower abdominal pain 2. lower abdominal tenderness and/or rebound tenderness 3. pyrexia (axillary temperature ≥ 37.5 °C), a WBC \> 10\*109/L on routine blood examination 4. Voluntary signing of written informed consent
Exclusion criteria
* patients with an allergy to nitroimidazole * patients with a history of antibiotic therapy within the last 48 hours * patients with any condition likely to require broad spectrum antibiotics * patients who can not evaluate the efficacy or difficult to complete the desired course of treatment * ALT and / or AST ≥ 1.5 times the ULN, and / or serum creatinine ≥ the ULN * patients with severe systemic diseases likely to affect therapy (e.g., cardiovascular abnormalities, unstable angina, high blood pressure, severe neuropathy, or epilepsy) * patients with other diseases or use other drugs which may interfere with the efficacy or safety of the drug * patients who participated other clinical trials within 6 months before the start of the trial * Pregnant women, breastfeeding women, women of childbearing age without effective contraceptive
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical cure Rate | 5-10 days | Clinical cure Rate （according to symptoms and signs） at 5-10 days post-therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Bacteriological response（Bacterial elimination rate） | 5-10 days | Bacteriological response (on the first day post-therapy, at 5-10 days post-therapy) |
| Clinical cure Rate on the first day | the first day | Clinical cure Rate（according to symptoms and signs）on the first day post-therapy |
| Tissue distribution | 5-10 days | Tissue distribution of target organ（Tissue of the appendix） |
| PPK parameters | 5-10 days | Area under the plasma concentration versus time curve (AUC) of morinidazole |
Countries
China
Contacts
Primary ContactYun Tang
Outcome results
None listed